Initiating therapy with antidepressants after discontinuation of hormone therapy

Menopause

Volumn 20, Issue 2, 2013, Pages 146-151

  Citarella, Anna ^a   Andersen, Morten ^a   Sundström, Anders ^a   Bardage, Carola ^b   Hultman, Christina M ^a   Kieler, Helle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Antidepressants; Epidemiology; Hormone therapy

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLIMACTERIUM; DEPRESSION; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PRESCRIPTION; TREATMENT DURATION;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PERIMENOPAUSE; POSTMENOPAUSE; REGISTRIES; SUBSTANCE WITHDRAWAL SYNDROME; SWEDEN;

EID: 84873410348     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182611590     Document Type: Article

References (42)

1. Fournier A, Weiderpass E. Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women. Climacteric 2009;12:410-418.
2. Thunell L, Stadberg E, Milsom I, Mattsson LA. Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstet Gynecol Scand 2005;84:395-401.
3. Oren A. Motives for initiation, temporary discontinuation, and permanent discontinuation of hormone replacement therapy use among Norwegian women. Maturitas 2009;64:33-37.
4. Freeman EW. Associations of depression with the transition to menopause. Menopause 2010;17:823-827.
5. Soares CN. Depression during the menopausal transition: window of vulnerability or continuum of risk? Menopause 2008;15:207-209.
6. Schmidt PJ, Rubinow DR. Sex hormones and mood in the perimenopause. Ann N Y Acad Sci 2009;1179:70-85.
7. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
8. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-382.
9. Judd FK, Hickey M, Bryant C. Depression and midlife: are we overpathologising the menopause? J Affect Disord 2012;136:199-211.
10. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transitionVthe Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-390.
11. Ancelin ML, Scali J, Ritchie K. Hormonal therapy and depression: are we overlooking an important therapeutic alternative? J Psychosom Res 2007; 62:473-485.
12. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
13. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
14. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal womenVprincipal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
15. Bren L. The estrogen and progestin dilemma: new advice, labeling guidelines. FDA Consum 2003;37:10-11.
16. European Agency for the Evaluation of Medicinal Products (EMEA). EMEA public statement on recent publications regarding hormone replacement therapy. Available at: http://www.cbg-meb.nl/NR/rdonlyres/7152423E-6A92-4018-89B2- F9EBA8B26CA8/0/20031203pbhrtemeadec03.pdf. Accessed November 14, 2011.
17. Kim N, Gross C, Curtis J, Stettin G, Wogen S, Choe N, et al. The impact of clinical trials on the use of hormone replacement therapyVa population-based study. J Gen Intern Med 2005;20:1026-1031.
18. McIntyre RS, Konarski JZ, Grigoriadis S, Fan NC, Mancini DA, Fulton KA, et al. Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ 2005;172:57-59.
19. Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
20. Grady D, Ettinger B, Tosteson ANA, et al. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102: 1233-1239.
21. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
22. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006;53:356-361.
23. Wettermark B, Harnmar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug RegisterV opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-735.
24. World Health Organization (WHO) Oslo. Guidelines for ATC classification and DDD assignment. WHO Collaborating Center for Drug Statistics Methodology, Oslo, 2005. Available at: www.whocc.no. Accessed November 14, 2011.
25. Olie JP, Elomari F, Spadone C, Lepine JP. Antidepressants consumption in the global population in France. Encephale 2002;28(5 pt 1):411-417.
26. Monte S, Macchia A, Romero M, D'Ettore A, Giuliani R, Tognoni G. Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk. Eur J Clin Pharmacol 2009;65:1131-1138.
27. Scali J, Ryan J, Carriere I, Dartiques JF, Tavernier B, Ritchie K, et al. A prospective study of hormone therapy and depression in communitydwelling elderly women: the Three City Study. J Clin Psychiatry 2010;71:1673-1679.
28. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-420.
29. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a doubleblind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58: 529-534.
30. Haas S, Walsh B, Evans S, Krache M, Ravnikar V, Schiff I. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988;71:671-676.
31. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319-336.
32. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977;4:31-47.
33. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998;44:839-850.
34. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-1314.
35. The North American Menopause Society. The 2012 hormone therapy position statement of The NorthAmericanMenopause Society.Menopause 2012;19:257-271.
36. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142:1103-1112.
37. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
38. Barton DL, LaVasseur BI, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-3283.
39. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E, Haiva-Mallinen L, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebocontrolled, double-blind study. Menopause 2005;12:18-26.
40. Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopausal hot flashes. Menopause 2011;18:893-896.
41. Bromberger JT, Kravitz HM, Chang YF, Cryanowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med 2011;41:1879-1888.
42. Jalava-Broman J, Makinen J, Ojanlatva A, Jokinen K, Sillanmaki L, Rautava P. Change in the frequency of HRT use from 2000 to 2005 and reasons to discontinue: follow-up of a normal cohort in Finland. Acta Obstet Gynecol Scand 2011;90:351-357.